NCT06430541View on ClinicalTrials.gov

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Breast CancerOvarian Cancer
Interventions
DRUG

Psilocybin

A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.

Trial Locations (2)

80045

RECRUITING

Outpatient CTRC, Aurora

RECRUITING

University of Colorado Cancer Center, Aurora

All Listed Sponsors
collaborator

Usona Institute

OTHER

lead

University of Colorado, Denver

OTHER